Ventricular fibrillations treatment

The treatment for ventricular fibrillation (VF) centers on immediate defibrillation, CPR, and pharmacologic support. The key steps are: unsynchronized DC shock (200J biphasic or 360J monophasic), high-quality CPR between shocks, epinephrine 1mg IV every 3-5 minutes, and amiodarone 300mg IV for shock-refractory VF.
Searching sources...
Reading File
Now I'll run parallel searches across the medical library and PubMed for comprehensive coverage.
Finding Sources
Searching PubMed

"ventricular fibrillation"[MeSH Terms] AND "defibrillation"[MeSH Terms]

Searching Images

ventricular fibrillation ECG waveform defibrillation treatment algorithm

This diagnostic image shows a single-lead electrocardiogram (ECG/EKG) strip plotted on standard red grid paper, demonstrating Ventricular Fibrillation (VF). The waveform is characterized by a chaotic, irregular, and disorganized rhythm. Key morphological features include the complete absence of identifiable P waves, QRS complexes, and T waves. The tracing displays fibrillatory waves with varying amplitudes and erratic vertical deflections, indicating a lack of coordinated ventricular contraction. The amplitude of these oscillations fluctuates, generally ranging across two small grid squares relative to the isoelectric baseline. This tracing is a classic representation of a shockable cardiac arrest rhythm, emphasizing the medical importance of rapid defibrillation in Advanced Cardiovascular Life Support (ACLS) protocols. It serves as a pedagogical tool for medical students and healthcare professionals to differentiate between organized rhythms and life-threatening ventricular arrhythmias.

This diagnostic image shows a single-lead electrocardiogram (ECG/EKG) strip plotted on standard red grid paper, demonstrating Ventricular Fibrillation (VF). The waveform is characterized by a chaotic, irregular, and disorganized rhythm. Key morphological features include the complete absence of identifiable P waves, QRS complexes, and T waves. The tracing displays fibrillatory waves with varying amplitudes and erratic vertical deflections, indicating a lack of coordinated ventricular contraction. The amplitude of these oscillations fluctuates, generally ranging across two small grid squares relative to the isoelectric baseline. This tracing is a classic representation of a shockable cardiac arrest rhythm, emphasizing the medical importance of rapid defibrillation in Advanced Cardiovascular Life Support (ACLS) protocols. It serves as a pedagogical tool for medical students and healthcare professionals to differentiate between organized rhythms and life-threatening ventricular arrhythmias.

This diagnostic image displays a series of six representative 5-second electrocardiogram (ECG) waveform segments (labeled a-f) illustrating the progression of ventricular fibrillation (VF) over time. The segments correspond to 1, 4, 6, 8, 10, and 12 minutes post-VF induction. Initially (1 min), the waveform shows high-amplitude, coarse VF with disorganized but rapid electrical activity. From 4 to 10 minutes, there is a visible trend toward 'fine' ventricular fibrillation, characterized by a progressive decrease in both amplitude and dominant frequency as the myocardium becomes increasingly ischemic and depleted of ATP. At 10 minutes (panel e), the rhythm is near-isoelectric with very low amplitude. However, at 12 minutes (panel f), following the initiation of oxygenated blood perfusion, there is a stark morphological shift back to high-amplitude, high-frequency coarse VF. This sequence demonstrates the clinical significance of myocardial oxygenation and metabolic state in influencing VF morphology and the potential for successful defibrillation (often correlated with AMSA—Amplitude Mid-frequency Spectrum Analysis).

This diagnostic image displays a series of six representative 5-second electrocardiogram (ECG) waveform segments (labeled a-f) illustrating the progression of ventricular fibrillation (VF) over time. The segments correspond to 1, 4, 6, 8, 10, and 12 minutes post-VF induction. Initially (1 min), the waveform shows high-amplitude, coarse VF with disorganized but rapid electrical activity. From 4 to 10 minutes, there is a visible trend toward 'fine' ventricular fibrillation, characterized by a progressive decrease in both amplitude and dominant frequency as the myocardium becomes increasingly ischemic and depleted of ATP. At 10 minutes (panel e), the rhythm is near-isoelectric with very low amplitude. However, at 12 minutes (panel f), following the initiation of oxygenated blood perfusion, there is a stark morphological shift back to high-amplitude, high-frequency coarse VF. This sequence demonstrates the clinical significance of myocardial oxygenation and metabolic state in influencing VF morphology and the potential for successful defibrillation (often correlated with AMSA—Amplitude Mid-frequency Spectrum Analysis).

This diagnostic image is a continuous rhythm strip (ECG trace) illustrating ventricular fibrillation, a life-threatening cardiac arrhythmia. The waveform is characterized by rapid, chaotic, and disorganized electrical activity. There is a total absence of identifiable P waves, QRS complexes, and T waves. The baseline is highly irregular, showing undulating oscillations with variable amplitudes and frequencies, consistent with the coarse ventricular fibrillation pattern. Annotated labels 'Initial Rhythm' and 'Point 1' indicate specific chronological markers during the clinical event recorded by emergency medical services. This tracing serves as a classic educational example of a shockable cardiac arrest rhythm requiring immediate defibrillation. It highlights the loss of coordinated ventricular contraction and the resulting hemodynamic collapse associated with this arrhythmia.

This diagnostic image is a continuous rhythm strip (ECG trace) illustrating ventricular fibrillation, a life-threatening cardiac arrhythmia. The waveform is characterized by rapid, chaotic, and disorganized electrical activity. There is a total absence of identifiable P waves, QRS complexes, and T waves. The baseline is highly irregular, showing undulating oscillations with variable amplitudes and frequencies, consistent with the coarse ventricular fibrillation pattern. Annotated labels 'Initial Rhythm' and 'Point 1' indicate specific chronological markers during the clinical event recorded by emergency medical services. This tracing serves as a classic educational example of a shockable cardiac arrest rhythm requiring immediate defibrillation. It highlights the loss of coordinated ventricular contraction and the resulting hemodynamic collapse associated with this arrhythmia.

Multi-panel physiological waveform series demonstrating hemodynamic changes during ventricular fibrillation (VF) and subsequent defibrillation in the context of a continuous-flow left ventricular assist device (CF-LVAD). The image consists of a grid with six time-sequenced panels (A-F) tracking four parameters: Flow rates (PF: Pump Flow in pink, PAF: Pulmonary Artery Flow in cyan), Pressures (LVP: Left Ventricular Pressure in green, AOP: Aortic Pressure in purple), Central Venous Pressure (CVP in dark blue), and Electrocardiogram (ECG in red). Panels B-E illustrate the progression of sustained VF over 60 minutes, characterized by disorganized ECG activity and a compensatory increase in CVP amplitude and baseline (rising from ~10 to 14 mmHg). During VF, LVP and AOP remain significantly depressed with low pulsatility. Panel F displays the hemodynamic recovery post-defibrillation, showing the restoration of organized QRS complexes on ECG, a return of high-amplitude rhythmic pulsatility in LVP/AOP, and a significant reduction in CVP toward a stable baseline, signifying successful conversion to sinus rhythm and restored biventricular output.

Multi-panel physiological waveform series demonstrating hemodynamic changes during ventricular fibrillation (VF) and subsequent defibrillation in the context of a continuous-flow left ventricular assist device (CF-LVAD). The image consists of a grid with six time-sequenced panels (A-F) tracking four parameters: Flow rates (PF: Pump Flow in pink, PAF: Pulmonary Artery Flow in cyan), Pressures (LVP: Left Ventricular Pressure in green, AOP: Aortic Pressure in purple), Central Venous Pressure (CVP in dark blue), and Electrocardiogram (ECG in red). Panels B-E illustrate the progression of sustained VF over 60 minutes, characterized by disorganized ECG activity and a compensatory increase in CVP amplitude and baseline (rising from ~10 to 14 mmHg). During VF, LVP and AOP remain significantly depressed with low pulsatility. Panel F displays the hemodynamic recovery post-defibrillation, showing the restoration of organized QRS complexes on ECG, a return of high-amplitude rhythmic pulsatility in LVP/AOP, and a significant reduction in CVP toward a stable baseline, signifying successful conversion to sinus rhythm and restored biventricular output.

Finding Sources
Searching PubMed

"ventricular fibrillation" AND "cardiac arrest" AND treatment

Good results. Now let me read the key textbook sections for detailed content.
Reading File
Reading File
Reading File
Excellent data. Let me fetch the key algorithm images and read a bit more on post-arrest care and refractory VF.
Loading Image
Loading Image
Reading File
I now have rich, authoritative content. Let me compile the full answer.

Ventricular Fibrillation (VF) - Treatment

What is VF?

Ventricular fibrillation is a life-threatening arrhythmia characterized by chaotic, disorganized electrical activity causing loss of coordinated ventricular contraction and hemodynamic collapse. On ECG it shows irregular fibrillatory waves with no identifiable P waves, QRS complexes, or T waves - a classic "shockable" cardiac arrest rhythm.
Classic VF ECG:
VF ECG - chaotic irregular waveform with no identifiable complexes

Treatment Algorithm

The complete management follows the ACLS shockable rhythm protocol:
VF/Pulseless VT Treatment Algorithm - Harrison's Principles of Internal Medicine

Step-by-Step Management

1. Immediate Recognition and CPR

  • Confirm unresponsiveness, absent pulse, and VF on monitor/defibrillator
  • Begin chest compressions immediately at 100-120/min, depth 5 cm (2 inches), allowing full chest recoil
  • Minimize interruptions - "hands-only CPR" is acceptable for lay rescuers
  • Ventilation: 2 breaths per 30 compressions if trained rescuer; continuous compressions otherwise
  • Activate emergency response system (call 911/EMS)
- Harrison's Principles of Internal Medicine 22e, p. 2336

2. Early Defibrillation (Priority #1)

  • Defibrillation is the definitive treatment for VF - it is the only intervention proven to terminate VF
  • Deliver a single unsynchronized shock:
    • Biphasic: 120-200 J (manufacturer-recommended energy; most use 200 J initially, escalate if needed to 360 J)
    • Monophasic: 360 J (fixed dose)
  • Immediately resume CPR for 2 minutes after each shock - do NOT pause to check rhythm first
  • Biphasic waveforms have a lower defibrillation threshold and reduce post-shock myocardial dysfunction compared to monophasic, though neither has proven superiority for ROSC or survival to discharge
- Rosen's Emergency Medicine, p. 80; Tintinalli's Emergency Medicine, p. 201

3. Vascular Access and Vasopressors

  • Establish IV or intraosseous (IO) access as soon as possible without interrupting CPR
  • Epinephrine 1 mg IV/IO - repeat every 3-5 minutes
    • Mechanism: alpha-1 vasoconstriction increases coronary perfusion pressure; allows drug to reach central circulation
    • Allow at least 30-60 seconds of CPR after drug administration before the next shock
  • Place defibrillation pads early so shocks can be delivered without pausing compressions
- Tintinalli's Emergency Medicine, p. 201

4. Antiarrhythmic Drugs (Shock-Refractory VF)

If VF persists after CPR, defibrillation, and epinephrine:
DrugDoseNotes
Amiodarone (first-line)300 mg IV push, then 150 mg if neededClass III antiarrhythmic; lowers defibrillation threshold
Lidocaine (alternative)1-1.5 mg/kg IV; repeat 0.5-0.75 mg/kg every 5-10 min (max 3 mg/kg)Use if amiodarone unavailable or contraindicated
Magnesium sulfate1-2 g IVOnly for torsades de pointes or hypomagnesemia-associated VF
- Rosen's Emergency Medicine (Fig. 5.1); Harrison's 22e; Tintinalli's Emergency Medicine

5. Advanced Airway

  • Endotracheal intubation or supraglottic airway when feasible, with minimal interruption of chest compressions

Special Situations and Cause-Specific Therapies

ConditionTreatment
Polymorphic VT/VF + Acute Coronary SyndromeLidocaine, emergent PCI/coronary revascularization
Torsades de Pointes (acquired long QT)Magnesium 1-2 g IV, transvenous pacing, isoproterenol
Brugada Syndrome / Idiopathic VFIsoproterenol, quinidine
Hyperkalemia-induced VFCalcium gluconate, sodium bicarbonate
WPW-related VFAvoid AV nodal blockers; electrical cardioversion
HypothermiaActive rewarming; VF may be refractory until core temp >30°C
- Harrison's Principles of Internal Medicine 22e

Refractory VF (3 or More Failed Shocks)

  • Double Sequential External Defibrillation (DSED): Two sets of defibrillation pads placed (standard apex-sternum + anterior-posterior), both charged to maximum, simultaneous shock delivery. Theorized to reduce VF threshold and override the refractory period. Appropriate after quality CPR and multiple failed defibrillations.
  • Address reversible causes (H's and T's):
    • H's: Hypoxia, Hypovolemia, Hydrogen ion (acidosis), Hypo/Hyperkalemia, Hypothermia
    • T's: Tension pneumothorax, Tamponade, Toxins, Thrombosis (PE or MI)
- Tintinalli's Emergency Medicine, p. 202

Post-Cardiac Arrest Care (After ROSC)

Once return of spontaneous circulation (ROSC) is achieved:
  1. 12-lead ECG immediately - assess for ST-elevation MI; emergent coronary angiography + PCI if STEMI present
  2. Hemodynamic stabilization: Target systolic BP >90 mmHg, mean arterial pressure >65 mmHg; vasopressors if needed
  3. Targeted Temperature Management (TTM): For comatose survivors, maintain temperature 32-36°C (evidence of neuroprotection); active prevention of fever (>37.7°C) is now the minimum standard per 2025 AHA guidelines
  4. Neurological monitoring: Brain injury accounts for >2/3 of post-ROSC deaths; multimodal prognostication at 72 hours
  5. Optimize ventilation: Avoid hypoxia and hypercapnia; target PaO2 94-98%, normocapnia
  6. Treat electrolyte abnormalities: Correct hypokalemia (target K >4 mEq/L), hypomagnesemia, and acidosis
- Harrison's Principles of Internal Medicine 22e, p. 2380

Long-Term Secondary Prevention

For survivors of VF:
  • Implantable Cardioverter-Defibrillator (ICD) - mainstay of secondary prevention; reduces recurrent SCD
  • Oral antiarrhythmics: Amiodarone as adjunct to ICD; sotalol in structural heart disease
  • Treat underlying cause: Coronary revascularization for ischemic VF; guideline-directed medical therapy for cardiomyopathy; catheter ablation for channelopathy-related or scar-mediated VF
  • Genetic evaluation if no structural heart disease is found (long QT, Brugada, CPVT, HCM screening)

Recent Evidence (2025 AHA Guidelines)

The 2025 AHA Adult Advanced Life Support Guidelines (PMID 41122884, Circulation 2025) provide current recommendations. A 2023 systematic review and network meta-analysis (PMID 37482919) specifically addresses defibrillation strategies for refractory out-of-hospital VF, with DSED showing improved ROSC over standard defibrillation in some analyses.

Key takeaway: Time to defibrillation is the single most important determinant of survival in VF. Every minute without defibrillation reduces survival by ~10%. High-quality CPR bridges the gap until the defibrillator is available and optimizes coronary perfusion between shocks.

Types of Myocardial infarction

Myocardial infarction (MI) is classified by several systems: by ECG pattern (STEMI vs NSTEMI), by depth of injury (transmural vs subendocardial), and by the Universal Classification into 5 types based on etiology (Type 1 = atherosclerotic plaque rupture, Type 2 = supply-demand mismatch, Types 3-5 = procedure/death-related).
Searching sources...
Reading File
Finding Sources
Finding Sources
Searching Images

types of myocardial infarction classification STEMI NSTEMI universal definition pathology

Summary : This figure presents the types and classification of Acute Coronary Syndromes, contrasting NSTEMI (Non-ST-Elevation Myocardial Infarction) and STEMI (ST-Elevation Myocardial Infarction) based on angiographic findings, electrocardiographic changes, and cardiac biomarker changes.

flowchart:
# Main Categories :
  • Acute Coronary Syndromes (central node)
    – Branches into: NSTEMI (left), STEMI (right)

# NSTEMI :
  ## Angiographic Findings :
    • Illustration of a coronary artery with a partially occlusive thrombus.
    • Label: "Partially occlusive thrombus"
  ## Electrocardiographic Changes :
    • ST-segment depression (example ECG tracing)
    • T-wave inversion (example ECG tracing)
    • Note: "Nonspecific or no electrocardiographic changes may instead be seen"
  ## Biomarker Change (cardiac troponin) :
    • Unstable angina: negative (–)
    • NSTEMI: positive (+)

# STEMI :
  ## Angiographic Findings :
    • Illustration of a coronary artery with a completely occlusive thrombus.
    • Label: "Completely occlusive thrombus"
  ## Electrocardiographic Changes :
    • ST-segment elevation (example ECG tracing)
    • Note: "ST-elevation in ≥2 contiguous leads on standard 12-lead ECG (or ST-elevation on posterior lead ECG)"
  ## Biomarker Change (cardiac troponin) :
    • Positive (+)
    • Note: "Might be – if short time from symptom onset"

# Layout :
  • Two-column comparison: NSTEMI (blue background, left), STEMI (yellow background, right)
  • Each column subdivided into three horizontal sections: Angiographic Findings, Electrocardiographic Changes, Biomarker Change

# Analysis :
  • NSTEMI is characterized by partial thrombus occlusion, ST-segment depression or T-wave inversion (or nonspecific ECG changes), and positive cardiac troponin.
  • STEMI is defined by complete thrombus occlusion, ST-segment elevation on ECG, and positive cardiac troponin (may be negative early after symptom onset).
  • The figure visually distinguishes the pathophysiology, ECG findings, and biomarker profiles of NSTEMI and STEMI, aiding in clinical differentiation.

Summary : This figure presents the types and classification of Acute Coronary Syndromes, contrasting NSTEMI (Non-ST-Elevation Myocardial Infarction) and STEMI (ST-Elevation Myocardial Infarction) based on angiographic findings, electrocardiographic changes, and cardiac biomarker changes. flowchart: # Main Categories : • Acute Coronary Syndromes (central node) – Branches into: NSTEMI (left), STEMI (right) # NSTEMI : ## Angiographic Findings : • Illustration of a coronary artery with a partially occlusive thrombus. • Label: "Partially occlusive thrombus" ## Electrocardiographic Changes : • ST-segment depression (example ECG tracing) • T-wave inversion (example ECG tracing) • Note: "Nonspecific or no electrocardiographic changes may instead be seen" ## Biomarker Change (cardiac troponin) : • Unstable angina: negative (–) • NSTEMI: positive (+) # STEMI : ## Angiographic Findings : • Illustration of a coronary artery with a completely occlusive thrombus. • Label: "Completely occlusive thrombus" ## Electrocardiographic Changes : • ST-segment elevation (example ECG tracing) • Note: "ST-elevation in ≥2 contiguous leads on standard 12-lead ECG (or ST-elevation on posterior lead ECG)" ## Biomarker Change (cardiac troponin) : • Positive (+) • Note: "Might be – if short time from symptom onset" # Layout : • Two-column comparison: NSTEMI (blue background, left), STEMI (yellow background, right) • Each column subdivided into three horizontal sections: Angiographic Findings, Electrocardiographic Changes, Biomarker Change # Analysis : • NSTEMI is characterized by partial thrombus occlusion, ST-segment depression or T-wave inversion (or nonspecific ECG changes), and positive cardiac troponin. • STEMI is defined by complete thrombus occlusion, ST-segment elevation on ECG, and positive cardiac troponin (may be negative early after symptom onset). • The figure visually distinguishes the pathophysiology, ECG findings, and biomarker profiles of NSTEMI and STEMI, aiding in clinical differentiation.

A comparative diagnostic image panel illustrating differences between ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) using angiographic blush quantification and cardiac magnetic resonance (CMR). The top row (a, b) displays STEMI findings: (a) an angiographic frame with a circular red Region of Interest (ROI) showing reduced myocardial blush, and (b) a delayed-enhancement CMR image showing extensive hyperenhancement (red arrows) indicating a large transmural inferior wall infarct. The bottom row (c, d) displays NSTEMI findings: (c) an angiographic frame with higher myocardial blush density within the ROI, and (d) a delayed-enhancement CMR image showing a small, localized area of subendocardial hyperenhancement (red arrow) in the anterior wall. The visual comparison highlights the greater infarct size and transmurality associated with STEMI compared to the smaller, non-transmural nature of NSTEMI, as well as the corresponding differences in microvascular perfusion (blush) between the two clinical presentations.

A comparative diagnostic image panel illustrating differences between ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) using angiographic blush quantification and cardiac magnetic resonance (CMR). The top row (a, b) displays STEMI findings: (a) an angiographic frame with a circular red Region of Interest (ROI) showing reduced myocardial blush, and (b) a delayed-enhancement CMR image showing extensive hyperenhancement (red arrows) indicating a large transmural inferior wall infarct. The bottom row (c, d) displays NSTEMI findings: (c) an angiographic frame with higher myocardial blush density within the ROI, and (d) a delayed-enhancement CMR image showing a small, localized area of subendocardial hyperenhancement (red arrow) in the anterior wall. The visual comparison highlights the greater infarct size and transmurality associated with STEMI compared to the smaller, non-transmural nature of NSTEMI, as well as the corresponding differences in microvascular perfusion (blush) between the two clinical presentations.

Summary : This flowchart presents a revised classification of myocardial infarction (MI) based on the presence or absence of acute coronary occlusion and the underlying mechanisms, as adapted from de Lemos et al. It visually distinguishes between MI with acute coronary occlusion and MI due to oxygen supply/demand mismatch without acute coronary occlusion, further subdividing each category by specific pathophysiological causes.

flowchart:
# Main Categories :
  • Acute myocardial injury with signs and/or symptoms of ischaemia (top-level node).
  • Two primary branches:
    – MI with acute coronary occlusion.
    – MI due to oxygen supply/demand mismatch without acute coronary occlusion.

# MI with Acute Coronary Occlusion (Left Branch) :
  • Plaque rupture/erosion with thrombus (circular illustration showing narrowed artery with thrombus).
  • Spontaneous coronary artery dissection (circular illustration showing dissection in artery wall).
  • Coronary embolism (circular illustration showing embolic obstruction).
  • Vasospasm or microvascular dysfunction (circular illustration showing narrowed vessel due to spasm).

# MI Due to Oxygen Supply/Demand Mismatch Without Acute Coronary Occlusion (Right Branch) :
  • With fixed obstructive CAD (circular illustration showing narrowed artery with stable plaque).
  • Without fixed obstructive CAD (circular illustration showing normal or non-obstructed artery).

# Connectors :
  • Downward arrows from the top node to the two main branches.
  • Further downward arrows from each main branch to their respective subcategories.

# Layout :
  • Hierarchical, top-down structure.
  • Two main branches split horizontally, each with multiple subcategories depicted with icons/illustrations.

# Technical Details :
  • Figure legend notes that both MI types may present with ECG changes of ST-segment elevation (STEMI) or non-ST-segment elevation (NSTEMI).
  • Abbreviations: CAD = coronary artery disease; MI = myocardial infarction.

Analysis :
  • The flowchart clarifies that MI can result from either acute coronary occlusion (with several distinct mechanisms) or from an imbalance in oxygen supply and demand without acute occlusion, with or without underlying coronary artery disease.
  • Visual icons help differentiate the pathophysiological processes, emphasizing the heterogeneity of MI causes.
  • The structure supports clinical differentiation for diagnosis and management.

Summary : This flowchart presents a revised classification of myocardial infarction (MI) based on the presence or absence of acute coronary occlusion and the underlying mechanisms, as adapted from de Lemos et al. It visually distinguishes between MI with acute coronary occlusion and MI due to oxygen supply/demand mismatch without acute coronary occlusion, further subdividing each category by specific pathophysiological causes. flowchart: # Main Categories : • Acute myocardial injury with signs and/or symptoms of ischaemia (top-level node). • Two primary branches: – MI with acute coronary occlusion. – MI due to oxygen supply/demand mismatch without acute coronary occlusion. # MI with Acute Coronary Occlusion (Left Branch) : • Plaque rupture/erosion with thrombus (circular illustration showing narrowed artery with thrombus). • Spontaneous coronary artery dissection (circular illustration showing dissection in artery wall). • Coronary embolism (circular illustration showing embolic obstruction). • Vasospasm or microvascular dysfunction (circular illustration showing narrowed vessel due to spasm). # MI Due to Oxygen Supply/Demand Mismatch Without Acute Coronary Occlusion (Right Branch) : • With fixed obstructive CAD (circular illustration showing narrowed artery with stable plaque). • Without fixed obstructive CAD (circular illustration showing normal or non-obstructed artery). # Connectors : • Downward arrows from the top node to the two main branches. • Further downward arrows from each main branch to their respective subcategories. # Layout : • Hierarchical, top-down structure. • Two main branches split horizontally, each with multiple subcategories depicted with icons/illustrations. # Technical Details : • Figure legend notes that both MI types may present with ECG changes of ST-segment elevation (STEMI) or non-ST-segment elevation (NSTEMI). • Abbreviations: CAD = coronary artery disease; MI = myocardial infarction. Analysis : • The flowchart clarifies that MI can result from either acute coronary occlusion (with several distinct mechanisms) or from an imbalance in oxygen supply and demand without acute occlusion, with or without underlying coronary artery disease. • Visual icons help differentiate the pathophysiological processes, emphasizing the heterogeneity of MI causes. • The structure supports clinical differentiation for diagnosis and management.

A multi-track genomic visualization showing the association of genetic variants at the 1p13.3 locus with myocardial infarction (MI) phenotypes. The top panel is a regional Manhattan-style plot displaying -log10(P) values for NSTEMI (red), STEMI (blue), and all MI (black) cases, distinguishing between genotyped (filled circles) and imputed (hollow triangles) variants. A gray shaded region highlights a cluster of high significance specifically for NSTEMI, with P-values reaching nearly 10^-9. Below the association plot, tracks display RefSeq genes including CD53, LRIF1, DRAM2, CEPT1, and DENND2D, alongside ENCODE regulatory annotations: Layered H3K27Ac peaks (marker of active enhancers/promoters) and DNase I hypersensitivity clusters (marker of open chromatin). The bottom track presents a Linkage Disequilibrium (LD) heat map using the D' statistic, revealing a distinct red block of high LD that corresponds spatially with the NSTEMI-associated variants and the DRAM2/CEPT1 gene region. This visual integration suggests a potential regulatory role of the identified variants in the pathogenesis of non-ST-elevation myocardial infarction.

A multi-track genomic visualization showing the association of genetic variants at the 1p13.3 locus with myocardial infarction (MI) phenotypes. The top panel is a regional Manhattan-style plot displaying -log10(P) values for NSTEMI (red), STEMI (blue), and all MI (black) cases, distinguishing between genotyped (filled circles) and imputed (hollow triangles) variants. A gray shaded region highlights a cluster of high significance specifically for NSTEMI, with P-values reaching nearly 10^-9. Below the association plot, tracks display RefSeq genes including CD53, LRIF1, DRAM2, CEPT1, and DENND2D, alongside ENCODE regulatory annotations: Layered H3K27Ac peaks (marker of active enhancers/promoters) and DNase I hypersensitivity clusters (marker of open chromatin). The bottom track presents a Linkage Disequilibrium (LD) heat map using the D' statistic, revealing a distinct red block of high LD that corresponds spatially with the NSTEMI-associated variants and the DRAM2/CEPT1 gene region. This visual integration suggests a potential regulatory role of the identified variants in the pathogenesis of non-ST-elevation myocardial infarction.

Excellent finds. Now let me read the detailed content from the key textbook sections in parallel.
Reading File
Reading File
Reading File
Reading File
Finding Sources
Searching PubMed

"myocardial infarction"[MeSH Terms] AND "classification"[MeSH Terms]

I now have all the necessary information. Let me also fetch the key classification diagram image.
Loading Image
Loading Image
I now have comprehensive, authoritative content to compile a detailed response.

Types of Myocardial Infarction

Myocardial infarction (MI) requires: (1) evidence of myocardial necrosis (rise and/or fall of cardiac troponin with at least one value above the 99th percentile upper reference limit), AND (2) clinical evidence of acute myocardial ischemia - whether symptoms, ECG changes, imaging findings, or coronary angiographic evidence. The classification of MI spans three overlapping frameworks.

Framework 1: ECG-Based Classification (Clinical Presentation)

This is the most clinically actionable classification, guiding immediate management decisions.
STEMI vs NSTEMI - Types and Classification of Acute Coronary Syndromes

STEMI (ST-Elevation Myocardial Infarction)

  • Pathology: Complete, total occlusion of an epicardial coronary artery by atherosclerotic plaque rupture/erosion + thrombus
  • ECG: ST-segment elevation in ≥2 contiguous leads (or new LBBB)
  • Extent: Typically transmural ischemia (full thickness of myocardial wall)
  • Biomarkers: Troponin positive (may be negative in the very early hours)
  • Treatment priority: Emergency reperfusion (primary PCI within 90 minutes, or thrombolytics within 30 minutes if PCI unavailable)

NSTEMI (Non-ST-Elevation Myocardial Infarction)

  • Pathology: Partial/incomplete coronary occlusion; partially occlusive thrombus
  • ECG: ST-segment depression, T-wave inversion, or nonspecific/no ECG changes
  • Extent: Typically subendocardial (inner layers of myocardium)
  • Biomarkers: Troponin positive (distinguishes NSTEMI from unstable angina, where troponin is negative)
  • Treatment: Early invasive strategy; urgent PCI within 24-72 hours

Unstable Angina (UA)

  • Ischemic symptoms at rest or with minimal exertion
  • No troponin elevation (no myocyte necrosis)
  • Managed similarly to NSTEMI but without confirmed infarction
Note: Previous terms "Q-wave MI" and "non-Q-wave MI" or "transmural" vs "subendocardial" MI have been abandoned - they did not adequately describe coronary pathophysiology or predict outcomes. STEMI and NSTEMI are the current standard. - Harrison's Principles of Internal Medicine 22e; Rosen's Emergency Medicine

Framework 2: Fourth Universal Definition - 5 Etiological Types

This is the authoritative global classification from the ESC/ACC/AHA Fourth Universal Definition of MI (2018).
Revised MI classification - occlusion vs supply-demand mismatch

Type 1 - Spontaneous MI (Atherothrombotic)

  • Mechanism: Atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection → intraluminal thrombosis → decreased myocardial blood flow or distal platelet emboli → myocyte necrosis
  • Coronary status: Usually severe CAD, but occasionally nonobstructive or no CAD (MINOCA - MI with Non-Obstructive Coronary Arteries)
  • Management: Invasive strategy, PCI; MINOCA managed medically
  • The most common type; classic "heart attack"

Type 2 - MI Secondary to Ischemic Imbalance

  • Mechanism: Supply-demand mismatch - NOT due to primary atherothrombosis, but a condition that either reduces myocardial oxygen supply or increases demand
  • Causes include:
    • Coronary artery spasm / vasospasm
    • Coronary embolism
    • Spontaneous coronary artery dissection (SCAD)
    • Tachyarrhythmia or bradyarrhythmia
    • Anemia
    • Respiratory failure / hypoxia
    • Hypotension or hypertension (with/without LV hypertrophy)
    • Coronary endothelial dysfunction
  • Key point: Management depends entirely on the underlying cause, not on the same protocol as Type 1
  • - Tietz Textbook of Laboratory Medicine 7e; Fuster and Hurst's The Heart 15e

Type 3 - MI Resulting in Death When Biomarkers Are Unavailable

  • Cardiac death with symptoms suggestive of myocardial ischemia AND presumed new ischemic ECG changes or new LBBB
  • Death occurs before blood samples could be obtained OR before cardiac biomarkers could rise
  • In rare cases, biomarkers were not collected at all
  • A diagnosis made retrospectively or at autopsy

Type 4 - PCI-Related MI

SubtypeDefinition
Type 4a - PCI-relatedTroponin elevation >5× the 99th percentile URL (in patients with normal baseline), PLUS at least one of: ischemic symptoms, new ECG changes/LBBB, angiographic loss of patency/slow flow/embolism, or imaging evidence of new infarction
Type 4b - Stent thrombosisMI detected by angiography or autopsy in the setting of ischemia, with troponin rise/fall with at least one value above 99th percentile URL
Type 4c - RestenosisMI associated with focal restenosis or diffuse in-stent restenosis on angiography

Type 5 - CABG-Related MI

  • Criterion: Troponin elevation >10× the 99th percentile URL in patients with normal baseline values, PLUS at least one of:
    • New pathologic Q waves or new LBBB
    • Angiographically documented new graft or new native coronary artery occlusion
    • Imaging evidence of new loss of myocardium or new regional wall motion abnormality
  • The very high troponin threshold accounts for the fact that cardiac surgery invariably causes some degree of myocardial injury
- Tietz Textbook of Laboratory Medicine 7e, BOX 48.3 (Thygesen et al., Fourth Universal Definition, JACC 2018)

Framework 3: Pathological/Anatomical Classification

CategoryDescription
Transmural MINecrosis spanning the full thickness of the ventricular wall; usually associated with complete coronary occlusion; classically produces pathologic Q waves
Subendocardial MINecrosis confined to the inner 1/3 to 1/2 of myocardial wall; associated with partial occlusion or supply-demand mismatch; usually no Q waves
Q-wave MIHistorical term; correlates roughly with transmural infarction; Q waves may disappear over time
Non-Q-wave MIHistorical term; correlates roughly with subendocardial infarction; now replaced by NSTEMI
Note: These older terms are imprecise - Q waves can appear in NSTEMI and be absent in STEMI. Modern CMR imaging has shown that transmurality and Q-wave presence do not always correlate. - Harrison's Principles of Internal Medicine 22e

By Territory / Location

LocationCulprit ArteryLeads Affected
Anterior MILAD (Left Anterior Descending)V1-V4
Anteroseptal MIProximal LADV1-V3
Lateral MILCx (Left Circumflex)I, aVL, V5-V6
Inferior MIRCA (Right Coronary Artery)II, III, aVF
Posterior MIRCA or LCxTall R in V1-V2; ST depression V1-V3 (reciprocal); ST elevation in V7-V9
Right Ventricular MIProximal RCAST elevation in right-sided leads (V3R, V4R)

Summary Table: Universal Classification

TypeNameKey FeatureTroponin Threshold
1SpontaneousPlaque rupture/thrombus>99th percentile URL
2Ischemic imbalanceSupply-demand mismatch>99th percentile URL
3Death before biomarkersPresumed ischemic deathN/A (unavailable)
4aPCI-relatedProcedure complication>5× URL
4bStent thrombosisConfirmed by angiography>99th percentile URL
5CABG-relatedSurgery complication>10× URL

Clinical Relevance: Why Type Matters

  • Type 1 → Antiplatelet therapy (aspirin + P2Y12 inhibitor), anticoagulation, PCI
  • Type 2 → Treat the underlying cause (control rate in arrhythmia, transfuse for anemia, relieve bronchospasm, etc.) - antiplatelet therapy may not be indicated
  • Type 3 → Autopsy/forensic context; presumptive treatment if any resuscitation attempted
  • Types 4-5 → Peri-procedural monitoring and prevention; different biomarker thresholds prevent over-diagnosis from normal surgical myocardial injury
  • MINOCA (a subset of Type 1/2) → Requires coronary angiography, ventriculography, and cardiac MRI to identify the mechanism; managed differently from obstructive CAD
- Fuster and Hurst's The Heart 15e, p. 646; Tietz Textbook of Laboratory Medicine 7e; Sabiston Textbook of Surgery
This is a shared conversation. Sign in to Orris to start your own chat.